Send Inquiry Send SMS
 Johnlee Pharmaceuticals Private Limited
 Johnlee Pharmaceuticals Private Limited  Banner

Rabeprazole Sodium 20mg Levosulpiride 75mg SR

Rabeprazole Sodium 20mg Levosulpiride 75mg SR
Rabeprazole Sodium 20mg Levosulpiride 75mg SR
Send Inquiry
Product Code : 290
Brand Name : Rabejohn LSR
Product Description

●Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD).
●Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
●Healing of Duodenal Ulcers
●Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome.
●Irritable bowel syndrome
●Chronic Gastritis.

Mechanism of Action:

Rabeprazole belongs to a class of anti secretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
Levosulpiride is more selective and acts primarily as a dopamine D2 antagonist. 
The prokinetic effect of Levosulpiride is mediated through the blockade of enteric (neuronal and muscular) inhibitory dopamine D2 receptors. Results also show that levosulpiride also acts as a moderate agonist at the 5-HT receptor. The serotonergic (5-HT4) component of Levosulpiride may enhance its therapeutic efficacy in gastrointestinal disorders. This property, together with antagonism at D2 receptors, may contribute to its gastrointestinal prokinetic effect. 

Drug Interactions: 
The effects on gastric motility can be antagonized by anticholinergic drugs, narcotics and opioid analgesics, that is, if administered together, Levosulpiride's gastroprokinetic efficacy can be decreased.
Association with psycho pharmaceutical drugs require special precautions and monitoring to avoid undesired and unexpected effects because of interactions. High doses can produce hyperprolactinemia, therefore special control during treatment is advised.
Rabeprazole produces a profound increase in gastric pH and may affect drugs whose absorption is pH dependant, such as ketoconazole and digoxin. Concomitant administration decreases ketoconazole levels by 33% and increases digoxin trough levels by up to 22%. 


Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome.
Levosulpiride acts as prokinetic agent. 


Absorption: Absolute bioavailability is approximately 52%.
Route of Elimination:Following a single 20 mg oral dose of 14C-labeled rabeprazole, Approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; itslucuronide, and mercapturic acid metabolites.

Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3hr.
Route of Elimination:Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV). 

Side Effects:
Headache, dizziness, diarrhoea, constipation, stomach pain, muscle weakness. 


AMBICA PHARMA All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.